Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1506 - Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory CLL: updated findings from an ongoing Phase 1a study

    Primary Author(s)

  • ZO

    Zulfa M. Omer, MD

    College of Medicine, University of Cincinnati
    Cincinnati, Ohio, United States

    • Co-Author(s)

  • Alexey V. Danilov, MD, PhD

    Professor
    Department of Hematology and Transplantation, City of Hope National Medical Center
    Duarte, California, United States

  • FF

    Francesco Forconi, MD

    University Hospital Southampton NHS Trust
    Southampton, England, United Kingdom

  • NS

    Nirav N. Shah, MD

    Medical College of Wisconsin
    Milwaukee, Wisconsin, United States

  • GC

    Graham P. Collins, MD

    Oxford Cancer and Haematology Centre, Churchill Hospital
    Oxford, England, United Kingdom

  • SM

    Shuo Ma, MD, PhD

    Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine
    Chicago, Illinois, United States

  • JR

    Jane Robertson, MD

    The Christie Hospital and Manchester Cancer Research Centre, Division of Cancer Sciences
    Manchester, England, United Kingdom

  • AA

    Alvaro J. Alencar, MD

    Associate Professor of Clinical Medicine
    University of Miami Sylvester Comprehensive Cancer Center
    Miami Beach, Florida, United States

  • Danielle M. Brander, MD

    Assistant Professor of Medicine, Division of Hematologic Malignancies & Cellular Therapy
    Duke University Medical Center
    Durham, North Carolina, United States

  • JB

    John C. C. Byrd, MD

    University of Cincinnati
    Cincinnati, Ohio, United States

  • DE

    Dima El-Sharkawi, MD

    Royal Marsden NHS Foundation Trust
    Sutton, England, United Kingdom

  • JS

    Jeffery Smith, MD

    The Clatterbridge Cancer Centre
    Liverpool, England, United Kingdom

  • AW

    Allison Winter, MD

    Taussig Cancer Institute, Cleveland Clinic
    Cleveland, Ohio, United States

    • Co-Author / Presenter(s)

  • MK

    Michal Kwiatek, MD

    AidPort Hospital
    Skórzewo (Poznan), Wielkopolskie, Poland

    • Co-Author(s)

  • JC

    Jonathon Cohen, MD

    Emory Winship Cancer Institute
    Atlanta, Georgia, United States

  • PI

    Prioty Islam, MD

    Memorial Sloan Kettering Cancer Center
    New York, New York, United States

  • SI

    Sarah G. Injac, MD

    Nurix Therapeutics, Inc.
    San Francisco, California, United States

  • Talha Munir, MBBS, MRCP, FRCPath, PhD

    Consultant Haematologist
    Leeds Teaching Hospitals NHS Trust
    Leeds, England, United Kingdom